Details of Disease

General Information of Disease (ID: DISOO0WT)

Disease Name	Epstein barr virus infection
Synonyms	Human Herpesvirus 4 infections; Human Herpes Virus 4 infections; infections, EBV; EBV infections; Virus infections, Epstein-Barr; Herpesvirus 4 infections, Human; Epstein Barr Virus infections; infections, Epstein-Barr Virus; Human gammaherpesvirus 4 caused disease or disorder; Epstein-Barr Virus infection; EBV infection; Human gammaherpesvirus 4 disease or disorder; Human gammaherpesvirus 4 infectious disease
Disease Class	1C80: Viral encephalitis
Definition	An infection that is caused by Epstein-Barr virus.
Disease Hierarchy	DISDI77C: Primary viral infectious disease DISEM33Q: Infectious disease DISOO0WT: Epstein barr virus infection
ICD Code	ICD-11 ICD-11: 1C80 ICD-9 ICD-9: 75 Expand ICD-9 75
Disease Identifiers	MONDO ID MONDO_0005111 MESH ID D020031 UMLS CUI C0149678 MedGen ID 57439 SNOMED CT ID 240530001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Allogeneic cytotoxic T-cell therapy	DMKRD4P	Phase 2	NA	[1]
MAU868	DM9F15C	Phase 1	Antibody	[2]
mRNA-1189	DM40551	Phase 1	Vaccine	[3]
mRNA-1195	DMFMZC9	Phase 1	Vaccine	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 39 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD19	TTW640A	Limited	Biomarker	[5]
CD274	TT8ZLTI	Limited	Biomarker	[6]
CLEC4C	TT7YT06	Limited	Biomarker	[7]
CR2	TT0HUN7	Limited	Biomarker	[8]
DUSP5	TTZN92A	Limited	Altered Expression	[9]
FCER2	TTCH6MU	Limited	Biomarker	[8]
HLA-DQA1	TTU2I3J	Limited	Genetic Variation	[10]
ITGB6	TTKQSXZ	Limited	Biomarker	[11]
ITGB7	TTLT9XQ	Limited	Altered Expression	[12]
ITK	TT3C80U	Limited	Genetic Variation	[13]
KLRG1	TT299E6	Limited	Biomarker	[14]
PGC	TT7K6AD	Limited	Altered Expression	[15]
RAPGEF3	TTOE7I0	Limited	Biomarker	[11]
XIAP	TTK3WBU	Limited	Biomarker	[16]
LPAR5	TTABCJ6	moderate	Altered Expression	[17]
MAGEC2	TTKGUEB	moderate	Biomarker	[18]
MAPKAPK2	TTMUG9D	moderate	Genetic Variation	[19]
AICDA	TTKRTP6	Strong	Biomarker	[20]
CCL3	TT8I4WB	Strong	Altered Expression	[21]
CD70	TTNCIE0	Strong	Biomarker	[22]
CD83	TTT9MRQ	Strong	Biomarker	[23]
CYP21A2	TTP4GLG	Strong	Genetic Variation	[10]
DKK2	TTST5KX	Strong	Genetic Variation	[24]
EHMT2	TTS6RZT	Strong	Genetic Variation	[10]
ENTPD1	TTYM8DJ	Strong	Altered Expression	[25]
EPHA4	TTG84D3	Strong	Altered Expression	[26]
FGR	TTPOGS1	Strong	Biomarker	[27]
GEM	TTAZF9M	Strong	Biomarker	[28]
GPR183	TTME5YJ	Strong	Altered Expression	[29]
IL10RB	TTJTRMK	Strong	Biomarker	[30]
PSMB9	TTOUSTQ	Strong	Biomarker	[31]
PTPN6	TT369M5	Strong	Posttranslational Modification	[32]
SSTR1	TTIND6G	Strong	Biomarker	[33]
STK4	TTCPLVN	Strong	Biomarker	[34]
TCL1A	TTUKRDV	Strong	Altered Expression	[35]
TNFRSF8	TT2GM5R	Strong	Altered Expression	[36]
VSIR	TT51SK8	Strong	Altered Expression	[37]
VTCN1	TTCK85E	Strong	Altered Expression	[38]
APCS	TTB7VAT	Definitive	Genetic Variation	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 39 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC35F3	DTEHSG0	Strong	Genetic Variation	[24]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
PGPEP1	DEVDR46	Limited	Altered Expression	[15]
HINT1	DEWJATF	moderate	Altered Expression	[39]
------------------------------------------------------------------------------------

This Disease Is Related to 75 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AGBL2	OTCX9987	Limited	Biomarker	[40]
ARID1A	OTRWDV3P	Limited	Genetic Variation	[41]
BCL2L12	OTS6IFZY	Limited	Genetic Variation	[11]
BCL7A	OTYFUJTP	Limited	Altered Expression	[42]
BPIFA1	OTQFD2J5	Limited	Biomarker	[43]
CAPNS1	OT95EBBD	Limited	Altered Expression	[44]
CD81	OTQFXNAZ	Limited	Altered Expression	[45]
CHRDL1	OTGMWVVA	Limited	Biomarker	[46]
DOK1	OTGVRLW6	Limited	Altered Expression	[47]
FAM72B	OT6AOG64	Limited	Biomarker	[48]
FBXO2	OTF3677S	Limited	Altered Expression	[49]
GPC4	OTUJ14DW	Limited	Genetic Variation	[50]
HNRNPU	OTLQN1E2	Limited	Biomarker	[11]
KLHDC8B	OTKP6LCR	Limited	Biomarker	[46]
LYST	OTIUB1B3	Limited	Genetic Variation	[51]
NIPAL1	OTRYI60X	Limited	Biomarker	[11]
NPC1	OTRIPICX	Limited	Genetic Variation	[52]
NUDT1	OTZSES3W	Limited	Altered Expression	[53]
POLE3	OTOELRF6	Limited	Biomarker	[48]
POU2F2	OTPV0J0C	Limited	Biomarker	[8]
PPRC1	OT6GB3WR	Limited	Biomarker	[54]
RASGRP1	OTX9WN2E	Limited	Biomarker	[22]
SENP2	OTPQJXIR	Limited	Biomarker	[55]
STXBP2	OTX8GUC4	Limited	Genetic Variation	[51]
TMEM72	OT6V5TCP	Limited	Genetic Variation	[56]
BLNK	OTSSPF6F	moderate	Posttranslational Modification	[18]
CD48	OT83ZNPP	moderate	Altered Expression	[57]
EBAG9	OTTQLQCP	moderate	Biomarker	[58]
FRK	OTEKV1SC	moderate	Altered Expression	[59]
GAGE1	OT53E50E	moderate	Altered Expression	[60]
GAGE4	OTPB5C0O	moderate	Altered Expression	[60]
GAGE5	OTFI6OVS	moderate	Altered Expression	[60]
GBP1	OTUM7RPJ	moderate	Altered Expression	[61]
GBP5	OTS4AO4A	moderate	Altered Expression	[61]
MED15	OT0D0JVD	moderate	Biomarker	[62]
MEPE	OTXJRUW0	moderate	Biomarker	[63]
NUPR2	OTNS6IEC	moderate	Altered Expression	[64]
PWWP3A	OTXQVL4U	moderate	Posttranslational Modification	[65]
RARRES1	OTETUPP5	moderate	Biomarker	[62]
SSB	OTCCTPBR	moderate	Biomarker	[66]
TNFAIP6	OT1SLUZH	moderate	Altered Expression	[61]
ACSBG1	OTM040MW	Strong	Biomarker	[67]
ADRM1	OTOU4EY6	Strong	Biomarker	[68]
ARL2BP	OT7REEDA	Strong	Biomarker	[69]
ATF5	OT03QCLM	Strong	Biomarker	[70]
BAG6	OT4Z0S2U	Strong	Genetic Variation	[10]
BSND	OTYWZWPD	Strong	Biomarker	[69]
BTNL2	OTTTEMZA	Strong	Genetic Variation	[10]
CSNK2B	OT2WW7R1	Strong	Genetic Variation	[10]
CTNNBIP1	OTX9SBJG	Strong	Altered Expression	[71]
FAM72A	OTBZYSR3	Strong	Biomarker	[48]
FGFBP2	OT3NBPQO	Strong	Genetic Variation	[56]
GPANK1	OT1TN2KT	Strong	Genetic Variation	[10]
HELLS	OTVVV668	Strong	Biomarker	[72]
HLA-DQB1	OTVVI3UI	Strong	Genetic Variation	[10]
HLA-DRA	OT7KZMP2	Strong	Genetic Variation	[10]
IRF5	OT8SIIAP	Strong	Biomarker	[73]
KDM2B	OTDMCVW7	Strong	Biomarker	[74]
KIR3DL1	OTPOSXFX	Strong	Biomarker	[28]
KRT1	OTIOJWA4	Strong	Altered Expression	[75]
LY6G5B	OTW89R8K	Strong	Genetic Variation	[10]
LY6G5C	OTC5GIUX	Strong	Genetic Variation	[10]
MACROD2	OTNQCHC6	Strong	Genetic Variation	[24]
MAGT1	OTQSAV5C	Strong	Genetic Variation	[76]
NRG3	OTIFZ5CT	Strong	Genetic Variation	[24]
PBX2	OTEBYCAW	Strong	Genetic Variation	[10]
POU5F1	OTDHHN7O	Strong	Genetic Variation	[24]
PRRC2A	OTBX6FM5	Strong	Genetic Variation	[10]
RAG2	OTG9UYTW	Strong	Genetic Variation	[77]
RAPH1	OTMQXW7S	Strong	Biomarker	[67]
SLC22A15	OT60WAAI	Strong	Genetic Variation	[24]
TCL1B	OT4CSO39	Strong	Altered Expression	[35]
TTN	OT0LZ058	Strong	Genetic Variation	[24]
SH2D1A	OTLU49I5	Definitive	Genetic Variation	[16]
SLAMF1	OTBTT3ZQ	Definitive	Biomarker	[78]
------------------------------------------------------------------------------------


⏷ Show the Full List of 75 DOT(s)

References

1	Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007 Aug 15;110(4):1123-31.
2	Clinical pipeline report, company report or official report of Amplyx Pharmaceuticals.
3	ClinicalTrials.gov (NCT05164094) A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults. U.S.National Institutes of Health.
4	ClinicalTrials.gov (NCT05831111) A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine, mRNA-1195, in Healthy Adults 18 to 55 Years of Age. U.S.National Institutes of Health.
5	Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-B signalling instead of B-cell receptor signalling.Hematol Oncol. 2017 Jun;35(2):187-197. doi: 10.1002/hon.2280. Epub 2016 Jan 22.
6	Revisiting the Tissue Microenvironment of Infectious Mononucleosis: Identification of EBV Infection in T Cells and Deep Characterization of Immune Profiles.Front Immunol. 2019 Feb 20;10:146. doi: 10.3389/fimmu.2019.00146. eCollection 2019.
7	Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus.Ann Neurol. 2010 Jun;67(6):726-38. doi: 10.1002/ana.21902.
8	American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.Ann Diagn Pathol. 2019 Apr;39:105-110. doi: 10.1016/j.anndiagpath.2019.02.001. Epub 2019 Feb 6.
9	Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.J Virol. 2020 Jan 31;94(4):e01837-19. doi: 10.1128/JVI.01837-19. Print 2020 Jan 31.
10	A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1).PLoS Genet. 2013;9(1):e1003147. doi: 10.1371/journal.pgen.1003147. Epub 2013 Jan 10.
11	Whole-Exome Sequencing of Nasopharyngeal Carcinoma Families Reveals Novel Variants Potentially Involved in Nasopharyngeal Carcinoma.Sci Rep. 2019 Jul 9;9(1):9916. doi: 10.1038/s41598-019-46137-4.
12	Epstein-Barr Virus Induces Expression of the LPAM-1 Integrin in B Cells In Vitro and In Vivo.J Virol. 2019 Feb 19;93(5):e01618-18. doi: 10.1128/JVI.01618-18. Print 2019 Mar 1.
13	ITK Gene Mutation: Effect on Survival of Children with Severe Hemophagocytic Lymphohistiocytosis.Indian J Pediatr. 2016 Nov;83(11):1349-1352. doi: 10.1007/s12098-016-2079-1. Epub 2016 Apr 8.
14	CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.PLoS Pathog. 2019 May 30;15(5):e1007748. doi: 10.1371/journal.ppat.1007748. eCollection 2019 May.
15	Epstein-Barr virus infection associated with pepsinogens and Helicobacter pylori infection in patients with gastric cancer.Virus Res. 2018 Sep 2;256:1-5. doi: 10.1016/j.virusres.2018.07.017. Epub 2018 Jul 24.
16	X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic.Eur J Pediatr. 2020 Feb;179(2):327-338. doi: 10.1007/s00431-019-03512-7. Epub 2019 Nov 21.
17	Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma.J Pathol. 2015 Feb;235(3):456-65. doi: 10.1002/path.4460. Epub 2014 Dec 18.
18	Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module.J Exp Med. 2001 Aug 6;194(3):255-64. doi: 10.1084/jem.194.3.255.
19	The effect of functional MAPKAPK2 copy number variation CNV-30450 on elevating nasopharyngeal carcinoma risk is modulated by EBV infection.Carcinogenesis. 2014 Jan;35(1):46-52. doi: 10.1093/carcin/bgt314. Epub 2013 Sep 20.
20	EBV in T-/NK-Cell Tumorigenesis.Adv Exp Med Biol. 2018;1045:459-475. doi: 10.1007/978-981-10-7230-7_21.
21	Epstein-Barr virus latent membrane protein-1 up-regulates cytokines and correlates with older age and poorer prognosis in Hodgkin lymphoma.Histopathology. 2017 Feb;70(3):442-455. doi: 10.1111/his.13085. Epub 2016 Nov 8.
22	Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility.EMBO Mol Med. 2018 Feb;10(2):188-199. doi: 10.15252/emmm.201708292.
23	The levels of soluble forms of CD21 and CD83 in multiple sclerosis.J Neuroimmunol. 2018 Jul 15;320:11-14. doi: 10.1016/j.jneuroim.2018.04.005. Epub 2018 Apr 13.
24	Genetic factors affecting EBV copy number in lymphoblastoid cell lines derived from the 1000 Genome Project samples.PLoS One. 2017 Jun 27;12(6):e0179446. doi: 10.1371/journal.pone.0179446. eCollection 2017.
25	Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group.J Clin Oncol. 1998 Dec;16(12):3788-95. doi: 10.1200/JCO.1998.16.12.3788.
26	Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival.Blood. 2016 Sep 22;128(12):1578-89. doi: 10.1182/blood-2016-02-702530. Epub 2016 Jun 23.
27	Regulation of c-fgr proto-oncogene expression in Epstein-Barr virus infected B-cell lines.Int J Cancer. 1990 Feb 15;45(2):342-6. doi: 10.1002/ijc.2910450222.
28	Epstein-Barr virus infections are strongly dependent on activating and inhibitory KIR-HLA pairs after T-cell replate unrelated hematopoietic stem cell transplantation, the principles, and method of pairing analysis.HLA. 2019 Dec;94 Suppl 2:40-48. doi: 10.1111/tan.13770.
29	EBI2 expression in B lymphocytes is controlled by the Epstein-Barr virus transcription factor, BRRF1 (Na), during viral infection.J Gen Virol. 2017 Mar;98(3):435-446. doi: 10.1099/jgv.0.000660. Epub 2017 Mar 20.
30	Bioinformatics analysis to reveal the key genes related to obstructive sleep apnea.Sleep Breath. 2019 Mar;23(1):259-267. doi: 10.1007/s11325-018-1694-7. Epub 2018 Jul 10.
31	Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.Protein Pept Lett. 2013 Oct;20(10):1136-43. doi: 10.2174/09298665113209990005.
32	Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma.Clin Chim Acta. 2009 Jun 27;404(2):128-33. doi: 10.1016/j.cca.2009.03.044. Epub 2009 Mar 29.
33	Somatostatin receptor 1, a novel EBV-associated CpG hypermethylated gene, contributes to the pathogenesis of EBV-associated gastric cancer.Br J Cancer. 2013 Jun 25;108(12):2557-64. doi: 10.1038/bjc.2013.263. Epub 2013 May 30.
34	EBV Negative Lymphoma and Autoimmune Lymphoproliferative Syndrome Like Phenotype Extend the Clinical Spectrum of Primary Immunodeficiency Caused by STK4 Deficiency.Front Immunol. 2018 Oct 16;9:2400. doi: 10.3389/fimmu.2018.02400. eCollection 2018.
35	TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma.Am J Clin Pathol. 2005 Oct;124(4):569-75. doi: 10.1309/77V7U4E03V69QHRR.
36	The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma.Pathology. 2003 Oct;35(5):428-35. doi: 10.1080/00313020310001602567.
37	The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?.Oncoimmunology. 2017 Feb 21;6(4):e1293215. doi: 10.1080/2162402X.2017.1293215. eCollection 2017.
38	B7-H4 is highly expressed in aggressive Epstein-Barr virus positive diffuse large B-cell lymphoma and inhibits apoptosis through upregulating Erk1/2 and Akt signalling pathways.Infect Agent Cancer. 2019 Aug 8;14:20. doi: 10.1186/s13027-019-0234-9. eCollection 2019.
39	Clinical significance of expression of Hint1 and potential epigenetic mechanism in gastric cancer.Int J Oncol. 2011 Jun;38(6):1557-64. doi: 10.3892/ijo.2011.994. Epub 2011 Apr 4.
40	Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients.PLoS One. 2018 May 10;13(5):e0197219. doi: 10.1371/journal.pone.0197219. eCollection 2018.
41	Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis.Saudi J Gastroenterol. 2017 Sep-Oct;23(5):268-274. doi: 10.4103/sjg.SJG_184_17.
42	Genipin as a novel chemical activator of EBV lytic cycle.J Microbiol. 2015 Feb;53(2):155-65. doi: 10.1007/s12275-015-4672-9. Epub 2015 Jan 28.
43	SPLUNC1 reduces the inflammatory response of nasopharyngeal carcinoma cells infected with the EB virus by inhibiting the TLR9/NF-B pathway.Oncol Rep. 2015 Jun;33(6):2779-88. doi: 10.3892/or.2015.3913. Epub 2015 Apr 17.
44	Capn4 is a marker of poor clinical outcomes and promotes nasopharyngeal carcinoma metastasis via nuclear factor-B-induced matrix metalloproteinase 2 expression.Cancer Sci. 2014 Jun;105(6):630-8. doi: 10.1111/cas.12416. Epub 2014 May 21.
45	Pre-stimulation of CD81 expression by resting B cells increases proliferation following EBV infection, but the overexpression of CD81 induces the apoptosis of EBV-transformed B cells.Int J Mol Med. 2015 Dec;36(6):1464-78. doi: 10.3892/ijmm.2015.2372. Epub 2015 Oct 13.
46	Epidemiology and outcome of chronic high Epstein-Barr viral load carriage in pediatric kidney transplant recipients.Pediatr Transplant. 2018 May;22(3):e13147. doi: 10.1111/petr.13147. Epub 2018 Feb 6.
47	Epstein-Barr virus down-regulates tumor suppressor DOK1 expression.PLoS Pathog. 2014 May 8;10(5):e1004125. doi: 10.1371/journal.ppat.1004125. eCollection 2014 May.
48	A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.Int J Cancer. 2015 Sep 15;137(6):1374-85. doi: 10.1002/ijc.29494. Epub 2015 Mar 9.
49	Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation.PLoS Pathog. 2018 Jul 27;14(7):e1007208. doi: 10.1371/journal.ppat.1007208. eCollection 2018 Jul.
50	The Glypican-4 Gene Polymorphism rs1048369 and Susceptibility to Epstein-Barr Virus-Positive and -Negative Nasopharyngeal Carcinoma in Northern China.Oncol Res Treat. 2019;42(11):572-579. doi: 10.1159/000502753. Epub 2019 Sep 13.
51	Novel mutations of STXBP2 and LYST associated with adult haemophagocytic lymphohistiocytosis with Epstein-Barr virus infection: a case report.BMC Med Genet. 2019 Feb 19;20(1):34. doi: 10.1186/s12881-019-0765-3.
52	Histocompatibility locus antigens regions contribute to the ethnicity bias of Epstein-Barr virus-associated nasopharyngeal carcinoma in higher-incidence populations.Scand J Immunol. 2019 Oct;90(4):e12796. doi: 10.1111/sji.12796. Epub 2019 Jul 23.
53	The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization.Oncogene. 2020 Jan;39(3):603-616. doi: 10.1038/s41388-019-1003-3. Epub 2019 Sep 11.
54	DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus.World J Gastroenterol. 2014 Apr 14;20(14):3916-26. doi: 10.3748/wjg.v20.i14.3916.
55	The Epstein-Barr Virus Oncoprotein, LMP1, Regulates the Function of SENP2, a SUMO-protease.Sci Rep. 2019 Jul 2;9(1):9523. doi: 10.1038/s41598-019-45825-5.
56	Killer-specific secretory (Ksp37) gene expression in subjects with Down's syndrome.Neurol Sci. 2016 May;37(5):793-5. doi: 10.1007/s10072-016-2554-5. Epub 2016 Mar 31.
57	Characterization of the CD48 gene demonstrates a positive element that is specific to Epstein-Barr virus-immortalized B-cell lines and contains an essential NF-kappa B site.J Virol. 1995 Feb;69(2):871-81. doi: 10.1128/JVI.69.2.871-881.1995.
58	Expression of human tumor-associated antigen RCAS1 in Reed-Sternberg cells in association with Epstein-Barr virus infection: a potential mechanism of immune evasion.Int J Cancer. 2001 Jul 1;93(1):91-6. doi: 10.1002/ijc.1300.
59	Epstein-barr virus gene expression, human leukocyte antigen alleles and chronic high viral loads in pediatric renal transplant patients.Transplantation. 2011 Aug 15;92(3):328-33. doi: 10.1097/TP.0b013e3182247bf2.
60	Relationship between GAGE-1/-2 expression, EBV infection and interferon-gamma expression in undifferentiated carcinoma of nasopharyngeal type.Anticancer Res. 2000 May-Jun;20(3A):1727-32.
61	Oligonucleotide microarray analysis of gene expression profiles followed by real-time reverse-transcriptase polymerase chain reaction assay in chronic active Epstein-Barr virus infection.J Infect Dis. 2008 Mar 1;197(5):663-6. doi: 10.1086/527330.
62	Role of the RARRES1 gene in nasopharyngeal carcinoma.Cancer Genet Cytogenet. 2009 Oct;194(1):58-64. doi: 10.1016/j.cancergencyto.2009.06.005.
63	Role of sexual behavior in the acquisition of asymptomatic Epstein-Barr virus infection: a longitudinal study.Pediatr Infect Dis J. 2005 Jun;24(6):498-502. doi: 10.1097/01.inf.0000164709.40358.b6.
64	Early events in Epstein-Barr virus infection of human B lymphocytes.Virology. 1991 Apr;181(2):595-608. doi: 10.1016/0042-6822(91)90893-g.
65	Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis.Minerva Med. 2004 Feb;95(1):53-64.
66	Epstein-Barr virus as an etiological agent in primary Sjgren's syndrome.Med Hypotheses. 1987 Apr;22(4):373-86. doi: 10.1016/0306-9877(87)90033-8.
67	Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders.Am J Pathol. 1997 Sep;151(3):805-12.
68	Epstein-Barr virus and rheumatoid arthritis.Autoimmun Rev. 2004 Jul;3(5):362-7. doi: 10.1016/j.autrev.2004.02.002.
69	Comprehensive profiling of Epstein-Barr virus-encoded miRNA species associated with specific latency types in tumor cells.Virol J. 2013 Oct 26;10:314. doi: 10.1186/1743-422X-10-314.
70	Up-regulation of activating transcription factor-5 suppresses SAP expression to activate T cells in hemophagocytic syndrome associated with Epstein-Barr virus infection and immune disorders.Am J Pathol. 2008 Nov;173(5):1397-405. doi: 10.2353/ajpath.2008.080440. Epub 2008 Oct 2.
71	CTNNBIP1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma.J Cell Physiol. 2019 Mar;234(3):2895-2904. doi: 10.1002/jcp.27106. Epub 2018 Aug 4.
72	Chromatin remodeling factor lymphoid-specific helicase links with Epstein-Barr virus associated the follicular germinal center B cell lymphomas.J Cancer Res Ther. 2019;15(2):350-357. doi: 10.4103/jcrt.JCRT_243_18.
73	Hypermethylation of the interferon regulatory factor 5 promoter in Epstein-Barr virus-associated gastric carcinoma.J Microbiol. 2015 Jan;53(1):70-6. doi: 10.1007/s12275-014-4654-3. Epub 2015 Jan 4.
74	Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.J Virol. 2019 Jun 14;93(13):e00273-19. doi: 10.1128/JVI.00273-19. Print 2019 Jul 1.
75	Soft and hard keratin expression in Epstein-Barr-virus-associated gastric carcinoma.Anticancer Res. 2005 Sep-Oct;25(5):3183-90.
76	Magnesium transporter 1 (MAGT1) deficiency causes selective defects in N-linked glycosylation and expression of immune-response genes.J Biol Chem. 2019 Sep 13;294(37):13638-13656. doi: 10.1074/jbc.RA119.008903. Epub 2019 Jul 23.
77	Leaky RAG Deficiency in Adult Patients with Impaired Antibody Production against Bacterial Polysaccharide Antigens.PLoS One. 2015 Jul 17;10(7):e0133220. doi: 10.1371/journal.pone.0133220. eCollection 2015.
78	SLAM-associated protein deficiency causes imbalanced early signal transduction and blocks downstream activation in T cells from X-linked lymphoproliferative disease patients.J Biol Chem. 2003 Aug 8;278(32):29593-9. doi: 10.1074/jbc.M300565200. Epub 2003 May 23.